Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy
Source abstract
Abstract
Chimeric antigen receptor (CAR) T cell therapy has recently shown unprecedented clinical efficacy for cancer treatment, particularly of hematological malignancies. However, the complex manufacturing processes that involve ex vivo genetic modification of autologous T cells limits its therapeutic application. CAR T cells generated in vivo provide a valid alternative immunotherapy, "off-the-shelf", for cancer treatment. This approach requires carriers for the delivery of CAR-encoding constructs, which are plasmid DNA or messenger RNA, to T cells for CAR expression to help eradicate the tumor. As such, there are a growing number of studies reporting gene delivery systems for in vivo CAR T cell therapy based on viral vectors and polymeric nanoparticles. Hyaluronic acid (HA) is a natural biopolymer that can serve for gene delivery, because of its inherent properties of cell recognition and internalization, as well as its biodegradability, biocompatibility, and presence of functional groups for the chemical conjugation of targeting ligands. In this review, the potential of HA in the delivery of CAR constructs is discussed on the basis of previous experience of HA-based nanoparticles for gene therapy. Furthermore, current studies on CAR carriers for in vivo-generated CAR T cells are included, giving an idea of a rational design of HA-based systems for the more efficient delivery of CAR to circulating T cells.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
Chulalongkorn University Cancer Immunology Excellence Center, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
Chulalongkorn University Stem Cell and Cell Therapy Research Center, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
3B's Research Group, I3Bs – Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark – Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal
ICVS/3B's – PT Government Associate Laboratory, Braga, Guimarães, Portugal
Center of Excellence in Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand
Funding
Asahi Glass Foundation · Chulalongkorn University
References (100+)
Show source-provided references
1. C. H.June , Chapter 30 - Adoptive Cellular Therapy With Synthetic T Cells as an “Instant Vaccine” for Cancer and Immunity , in The Vaccine Book , ed. B. R. Bloom and P.-H. Lambert , Academic Press , 2nd edn, 2016 , pp. 581–59610.1016/B978-0-12-802174-3.00030-8 ↗
2. X.Wang and M. I.Nishimura , Chapter 18 - Genetically Engineered (T Cell Receptor) T Cells for Adoptive Therapy , in Gene Therapy of Cancer , ed. E. C. Lattime and S. L. Gerson , Academic Press , San Diego , 3rd edn, 2014 , pp. 259–27110.1016/B978-0-12-394295-1.00018-4 ↗
3. Mullard · Nat. Rev. Drug Discovery · 2021 · 20 · 166
4. Parayath · Annu. Rev. Biomed. Eng. · 2021 · 23 · 38510.1146/annurev-bioeng-070620-033348 ↗
5. Guedan · Mol. Ther.–Methods Clin. Dev. · 2019 · 12 · 14510.1016/j.omtm.2018.12.009 ↗
6. Mhaidly · Mol. Ther. · 2019 · 27 · 70710.1016/j.ymthe.2019.03.012 ↗
7. Bonifant · Mol. Ther.–Oncolytics · 2016 · 3 · 1601110.1038/mto.2016.11 ↗
8. Xin · Front. Oncol. · 2022 · 12 · 1
9. Vasir · Expert Opin. Drug Delivery · 2006 · 3 · 32510.1517/17425247.3.3.325 ↗
10. Yoon · J. Controlled Release · 2013 · 172 · 65310.1016/j.jconrel.2013.09.008 ↗
11. R.Rotem , D.Prosperi and M.Colombo , Chapter 10 - Targeted delivery of nanoparticles , in Frontiers of Nanoscience , ed. W. J. Parak and N. Feliu , Elsevier , 2020 , pp. 253–264
12. Cevaal · ACS Nano · 2021 · 15 · 373610.1021/acsnano.0c09514 ↗
13. Lee-Sayer · Front. Immunol. · 2015 · 6 · 15010.3389/fimmu.2015.00150 ↗
14. Kumar · Immunity · 2018 · 48 · 20210.1016/j.immuni.2018.01.007 ↗
15. M. M. A.Abdel-Mottaleb , H.Abd-Allah , R. I.El-Gogary and M.Nasr , Chapter 1 - Versatile hyaluronic acid nanoparticles for improved drug delivery , in Drug Delivery Aspects , ed. R. Shegokar , Elsevier , 2020 , pp. 1–18
16. Schreiber Robert · Science · 2011 · 331 · 156510.1126/science.1203486 ↗
17. Mittal · Curr. Opin. Immunol. · 2014 · 27 · 1610.1016/j.coi.2014.01.004 ↗
18. Hayes · Ir. J. Med. Sci. · 2021 · 190 · 4110.1007/s11845-020-02264-w ↗
19. Saleh · Semin. Cancer Biol. · 2020 · 65 · 1310.1016/j.semcancer.2019.07.017 ↗
20. Rosenberg · Science · 2015 · 348 · 6210.1126/science.aaa4967 ↗
21. Liu · Front. Oncol. · 2022 · 11 · 1
22. Zhao · Front. Immunol. · 2021 · 12 · 1
23. June Carl · Science · 2018 · 359 · 136110.1126/science.aar6711 ↗
24. Holzinger · Immunotherapy · 2016 · 65 · 1433
25. Pack · Nat. Rev. Drug Discovery · 2005 · 4 · 58110.1038/nrd1775 ↗
26. Kawakami · J. Pharm. Sci. · 2008 · 97 · 72610.1002/jps.21024 ↗
27. M. A.Liu and J. B.Ulmer , Human Clinical Trials of Plasmid DNA Vaccines, Advances in Genetics , Academic Press , 2005 , pp. 25–40
28. Jackson · Nat. Rev. Drug Discovery · 2010 · 9 · 5710.1038/nrd3010 ↗
29. Ibraheem · Int. J. Pharm. · 2014 · 459 · 7010.1016/j.ijpharm.2013.11.041 ↗
30. Chung · ACS Nano · 2020 · 14 · 1252210.1021/acsnano.0c07197 ↗
31. Suk · Adv. Drug Delivery Rev. · 2016 · 99 · 2810.1016/j.addr.2015.09.012 ↗
32. Huang · J. Controlled Release · 2018 · 278 · 12210.1016/j.jconrel.2018.04.015 ↗
33. Kogan · Biotechnol. Lett. · 2007 · 29 · 1710.1007/s10529-006-9219-z ↗
34. Tirella · Int. J. Pharm. · 2019 · 561 · 11410.1016/j.ijpharm.2019.02.032 ↗
35. Park · Carbohydr. Polym. · 2016 · 136 · 79110.1016/j.carbpol.2015.09.053 ↗
36. Sun · J. Am. Chem. Soc. · 2015 · 137 · 600010.1021/jacs.5b01435 ↗
37. Yang · Biomaterials · 2020 · 255 · 12019410.1016/j.biomaterials.2020.120194 ↗
38. Sun · Drug Delivery · 2009 · 16 · 35710.1080/10717540903059549 ↗
39. He · Biomaterials · 2013 · 34 · 123510.1016/j.biomaterials.2012.09.049 ↗
40. Yin · Int. J. Pharm. · 2015 · 483 · 16910.1016/j.ijpharm.2015.02.022 ↗
41. de la Fuente · Invest. Ophthalmol. Visual Sci. · 2008 · 49 · 201610.1167/iovs.07-1077 ↗
42. Choi · Biomaterials · 2014 · 35 · 712110.1016/j.biomaterials.2014.04.096 ↗
43. Ito · J. Drug Targeting · 2008 · 16 · 27610.1080/10611860801900728 ↗
44. Lee · J. Controlled Release · 2014 · 192 · 12210.1016/j.jconrel.2014.06.049 ↗
45. Ito · Biomaterials · 2010 · 31 · 291210.1016/j.biomaterials.2009.12.032 ↗
46. Zhu · ACS Appl. Mater. Interfaces · 2022 · 14 · 509010.1021/acsami.1c23069 ↗
47. Benjaminsen · Mol. Ther. · 2013 · 21 · 14910.1038/mt.2012.185 ↗
48. Lallana · Mol. Pharm. · 2017 · 14 · 242210.1021/acs.molpharmaceut.7b00320 ↗
49. Yan · Adv. Funct. Mater. · 2015 · 25 · 390710.1002/adfm.201500695 ↗
50. Lee · J. Controlled Release · 2007 · 119 · 24510.1016/j.jconrel.2007.02.011 ↗
51. Mok · Bioconjugate Chem. · 2007 · 18 · 148310.1021/bc070111o ↗
52. Ganesh · J. Controlled Release · 2013 · 172 · 69910.1016/j.jconrel.2013.10.016 ↗
53. Aldawsari · Mol. Pharm. · 2019 · 16 · 12810.1021/acs.molpharmaceut.8b00904 ↗
54. Ganesh · Biomaterials · 2013 · 34 · 348910.1016/j.biomaterials.2013.01.077 ↗
55. Qhattal · ACS Nano · 2014 · 8 · 542310.1021/nn405839n ↗
56. Yang · Pharm. Res. · 2015 · 32 · 209710.1007/s11095-014-1602-1 ↗
57. Forman · Mol. Aspects Med. · 2009 · 30 · 110.1016/j.mam.2008.08.006 ↗
58. Saito · Adv. Drug Delivery Rev. · 2003 · 55 · 19910.1016/S0169-409X(02)00179-5 ↗
59. Yeh · RSC Adv. · 2013 · 3 · 1292210.1039/c3ra40880a ↗
60. Park · Biomaterials · 2010 · 31 · 525810.1016/j.biomaterials.2010.03.018 ↗
61. Chen · Drug Delivery · 2022 · 29 · 57410.1080/10717544.2022.2032874 ↗
62. Gwak · J. Biomater. Sci., Polym. Ed. · 2012 · 23 · 143710.1163/092050611X584090 ↗
63. Gan · Biomaterials · 2013 · 34 · 597810.1016/j.biomaterials.2013.04.035 ↗
64. Jiang · Mol. Pharm. · 2009 · 6 · 72710.1021/mp800176t ↗
65. Ito · J. Controlled Release · 2006 · 112 · 38210.1016/j.jconrel.2006.03.013 ↗
66. Spadea · Mol. Pharm. · 2019 · 16 · 248110.1021/acs.molpharmaceut.9b00083 ↗
67. Jordan · Front. Immunol. · 2015 · 6 · 18210.3389/fimmu.2015.00182 ↗
68. Kim · Polymer · 2018 · 10 · 110.1016/j.polymer.2017.12.040 ↗
69. Lee · Cancers · 2020 · 12 · 1
70. Deng · J. Mater. Sci.: Mater. Med. · 2018 · 29 · 155
71. Peer · Science · 2008 · 319 · 62710.1126/science.1149859 ↗
72. Wu · Carbohydr. Polym. · 2016 · 138 · 4910.1016/j.carbpol.2015.11.044 ↗
73. Tran · Sci. Rep. · 2015 · 5 · 1663210.1038/srep16632 ↗
74. Lu · PLoS One · 2013 · 8 · e6995010.1371/journal.pone.0069950 ↗
75. Liang · Mol. Pharm. · 2018 · 15 · 50810.1021/acs.molpharmaceut.7b00890 ↗
76. Wan · J. Controlled Release · 2020 · 322 · 23610.1016/j.jconrel.2020.03.015 ↗
77. Cohen · ACS Nano · 2015 · 9 · 158110.1021/nn506248s ↗
78. He · Adv. Mater. · 2020 · 32 · 200020810.1002/adma.202000208 ↗
79. Ren · ACS Appl. Bio Mater. · 2020 · 3 · 783110.1021/acsabm.0c01009 ↗
80. Jiang · Physiol. Rev. · 2011 · 91 · 22110.1152/physrev.00052.2009 ↗
81. Misra · Front. Immunol. · 2015 · 6 · 20110.3389/fimmu.2015.00201 ↗
82. Rios de la Rosa · Adv. Healthcare Mater. · 2019 · 8 · 190118210.1002/adhm.201901182 ↗
83. Bachar · Biomaterials · 2011 · 32 · 484010.1016/j.biomaterials.2011.03.040 ↗
84. Maeshima · Eur. J. Immunol. · 2011 · 41 · 110810.1002/eji.201040870 ↗
85. DeGrendele · J. Immunol. · 1997 · 159 · 254910.4049/jimmunol.159.6.2549 ↗
86. Lesley · J. Exp. Med. · 1994 · 180 · 38310.1084/jem.180.1.383 ↗
87. Evanko · Matrix Biol. · 2012 · 31 · 9010.1016/j.matbio.2011.10.004 ↗
88. Camp · J. Exp. Med. · 1993 · 178 · 49710.1084/jem.178.2.497 ↗
89. DeGrendele · Science · 1997 · 278 · 67210.1126/science.278.5338.672 ↗
90. Ariel · Immunology · 2000 · 100 · 34510.1046/j.1365-2567.2000.00059.x ↗
91. Bendall · Leukemia · 2000 · 14 · 123910.1038/sj.leu.2401830 ↗
92. Liebisch · Haematologica · 2005 · 90 · 489
93. Kawabata · Pharm. Res. · 1995 · 12 · 82510.1023/A:1016248701505 ↗
94. Akhtar · Trends Pharmacol. Sci. · 1997 · 18 · 1210.1016/S0165-6147(96)01002-4 ↗
95. Hagiwara · Biomaterials · 2012 · 33 · 725110.1016/j.biomaterials.2012.06.040 ↗
96. Ito · J. Pharm. Sci. · 2014 · 103 · 17910.1002/jps.23768 ↗
97. Bobisse · Expert Opin. Biol. Ther. · 2007 · 7 · 89310.1517/14712598.7.6.893 ↗
98. Levine · Mol. Ther.–Methods Clin. Dev. · 2017 · 4 · 9210.1016/j.omtm.2016.12.006 ↗
99. Bulcha · Signal Transduction Targeted Ther. · 2021 · 6 · 5310.1038/s41392-021-00487-6 ↗
100. Nawaz · Blood Cancer J. · 2021 · 11 · 11910.1038/s41408-021-00508-1 ↗